Somaxon touts mid-stage data on smoking cessation
Somaxon is touting new Phase II data for oral nalmefene hydrochloride for smoking cessation. Researchers said that a statistically superior number of patients taking a 40 milligram dose reported higher abstinence rates compared to a placebo. Patients in the 80 milligram group did not demonstrate a significantly higher rate of abstention.
"We are encouraged by the results of our first smoking cessation clinical study which was designed to be exploratory in nature," said Chief Medical Officer Phil Jochelson. "We are intrigued with the observation that the nalmefene 40 mg treated patients maintained higher abstinence rates relative to placebo."
- see the report on the data from Trading Markets
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
